|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2005-4-25
|
|
pubmed:abstractText |
The clinical significance of coexpression of type 1 growth factor receptor (T1GFR) family members remains largely unknown. The objective of the current study was to determine the frequency and the possible prognostic effect of coexpression of HER-1, HER-2, HER-3, and HER-4 by breast carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2005 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
103
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1770-7
|
|
pubmed:dateRevised |
2011-11-2
|
|
pubmed:meshHeading |
pubmed-meshheading:15770691-Breast Neoplasms,
pubmed-meshheading:15770691-Drug Synergism,
pubmed-meshheading:15770691-Female,
pubmed-meshheading:15770691-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15770691-Humans,
pubmed-meshheading:15770691-Lymph Nodes,
pubmed-meshheading:15770691-Neoplasm Invasiveness,
pubmed-meshheading:15770691-Neoplasm Staging,
pubmed-meshheading:15770691-Prognosis,
pubmed-meshheading:15770691-Receptor, Epidermal Growth Factor,
pubmed-meshheading:15770691-Receptor, erbB-2,
pubmed-meshheading:15770691-Receptor, erbB-3,
pubmed-meshheading:15770691-Survival Rate,
pubmed-meshheading:15770691-Tumor Markers, Biological
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
|
|
pubmed:affiliation |
Genetic Pathology Evaluation Center at the Prostate Research Center of Vancouver General Hospital & British Columbia Cancer Agency, Vancouver, British Columbia, Canada. smwiseman@providencehealth.bc.ca
|
|
pubmed:publicationType |
Journal Article
|
